Clinical mass spectrometry serves as a quantitative and qualitative analytical tool for assessment of complex mixtures in all the phases of drug development, including identification of the lead compound and their conformational details. Clinical laboratories use automation for the management of large number of samples through, either total automation systems or high level analyzer automation that are offered by clinical mass spectrometers such as Matrix Assisted Laser Desorption/Ionization (MALDI-TOF). These automated platforms assist effective processing of increasingly large workloads. Thus, clinical laboratories are among the largest end users of this technique. Moreover, the advancement in technology over the recent past, has enabled the ease of measuring and distinguishing separate contributions of molecules such as thyroid hormones and 25-hydroxyl vitamins D2 and D3. Application of translational research in the field of mass spectrometry has resulted in the discovery of blood-based biomarkers, endogenous metabolites, tumor markers, and new disease biomarkers. These advancements are expected to fuel adoption of clinical mass spectrometry devices.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/193
Clinical diagnostic mass spectrometers have the capacity to analyze a limited range of samples such as biomarkers, proteins or drug molecules at once, even in cases of low concentrations thus, making them a valuable tool for diagnostic medical laboratories. Furthermore, it allows researchers to determine pharmacokinetic profiles of drugs that are administered in microdoses. The technology shift from traditional systems to high-resolution technologies such as the Quadrupole-Time of Flight (Q-TOF) mass spectrometry is expected to grow rapidly due to its benefits of accuracy, improved resolution, and sensitivity for clinical diagnostic applications.
The global clinical mass spectrometry market is estimated to be valued at US$ 4,982.5 million in 2017 and is expected to witness a CAGR of 7.3% over the forecast period (2017 – 2025).
Clinical mass spectrometry offers significant advantages related to clinical research and forensic toxicology applications in terms of speed, robustness, simplicity, and selectivity of small molecules. Clinical mass spectrometry manufacturers are continuously collaborating with clinical diagnostic companies to retain the market share for new products that can quantify low trace levels of disease biomarkers. In Cambridge (U.S.) Thermo Fisher is advancing proteomics and clinical translational research through collaborations at the Biomarkers Research Initiatives in mass spectrometry center. Furthermore, increasing demand for clinical mass spectrometry to perform diagnostic assays in the field of endocrinology, toxicology, leukemia, and biochemical genetics, which helps overcome limitations of conventional immunoassays is also expected to create a favorable environment for growth of the market over the forecast period.
Key companies covered as part of this study include Agilent Technologies , Waters, Shimadzu Corporation, Danaher, PerkinElmer Inc., Thermo Fisher Scientific Inc., Bruker, Mass Spectrometry Instruments (MSI), and Kore technology
Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/193